Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

Neutralization against B.1.351 and B.1.617.2 with sera of COVID-19 recovered cases and vaccinees of BBV152

Pragya D. Yadav, Gajanan N. Sapkal, Raches Ella, Rima R. Sahay, Dimpal A Nyayanit, Deepak Y. Patil, Gururaj Deshpande, Anita M. Shete, Nivedita Gupta, V. Krishna Mohan, Priya Abraham, Samiran Panda, Balram Bhargava
doi: https://doi.org/10.1101/2021.06.05.447177
Pragya D. Yadav
1Indian Council of Medical Research-National Institute of Virology, Pune, IndiaPin-411021
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: hellopragya22@gmail.com
Gajanan N. Sapkal
1Indian Council of Medical Research-National Institute of Virology, Pune, IndiaPin-411021
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raches Ella
2Bharat Biotech International Limited, Genome Valley, Hyderabad, Telangana, India Pin-500 078
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rima R. Sahay
1Indian Council of Medical Research-National Institute of Virology, Pune, IndiaPin-411021
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dimpal A Nyayanit
1Indian Council of Medical Research-National Institute of Virology, Pune, IndiaPin-411021
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Deepak Y. Patil
1Indian Council of Medical Research-National Institute of Virology, Pune, IndiaPin-411021
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gururaj Deshpande
1Indian Council of Medical Research-National Institute of Virology, Pune, IndiaPin-411021
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anita M. Shete
1Indian Council of Medical Research-National Institute of Virology, Pune, IndiaPin-411021
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nivedita Gupta
3Indian Council of Medical Research, V. Ramalingaswami Bhawan, Ansari Nagar, New Delhi, India Pin-110029
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
V. Krishna Mohan
2Bharat Biotech International Limited, Genome Valley, Hyderabad, Telangana, India Pin-500 078
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Priya Abraham
1Indian Council of Medical Research-National Institute of Virology, Pune, IndiaPin-411021
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samiran Panda
3Indian Council of Medical Research, V. Ramalingaswami Bhawan, Ansari Nagar, New Delhi, India Pin-110029
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Balram Bhargava
3Indian Council of Medical Research, V. Ramalingaswami Bhawan, Ansari Nagar, New Delhi, India Pin-110029
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Preview PDF
Loading

Abstract

Recently, multiple SARS-CoV-2 variants have been detected across the globe. The recent emergence of B.1.617 lineage has created serious public health problem in India. The high transmissibility was observed with this lineage which has led to daily increase in the number of SARS-CoV-2 infections. Apparently, the sub-lineage B.1.617.2 has slowly dominated the other variants including B1617.1, B.617.3 and B.1.1.7. With this, World Health Organization has described B.1.617.2 as variant of concern. Besides this, variant of concern B.1.351 has been also reported from India, known to showreducedefficacyfor many approved vaccines. With the increasing threat of the SARS-CoV-2 variants, it is imperative to assess the efficacy of the currently available vaccines against these variants. Here, we have evaluated the neutralization potential of sera collected from COVID-19 recovered cases (n=20) and vaccinees with two doses of BBV152 (n=17) against B.1.351 and B.1.617.2 compared to the prototype B.1 (D614G) variant.The finding of the study demonstrated a reduction in neutralization titers with sera of COVID-19 recovered cases(3.3-fold and 4.6-fold) and BBV152 vaccinees (3. 0 and 2.7 fold) against B.1.351 and B.1.617.2 respectively.Although, there is reduction in neutralization titer, the whole-virion inactivated SARS-CoV-2 vaccine (BBV152) demonstrates protective response against VOC B.1351 and B.1.617.2.

Competing Interest Statement

The authors have declared no competing interest.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted June 07, 2021.
Download PDF
Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Neutralization against B.1.351 and B.1.617.2 with sera of COVID-19 recovered cases and vaccinees of BBV152
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Neutralization against B.1.351 and B.1.617.2 with sera of COVID-19 recovered cases and vaccinees of BBV152
Pragya D. Yadav, Gajanan N. Sapkal, Raches Ella, Rima R. Sahay, Dimpal A Nyayanit, Deepak Y. Patil, Gururaj Deshpande, Anita M. Shete, Nivedita Gupta, V. Krishna Mohan, Priya Abraham, Samiran Panda, Balram Bhargava
bioRxiv 2021.06.05.447177; doi: https://doi.org/10.1101/2021.06.05.447177
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Neutralization against B.1.351 and B.1.617.2 with sera of COVID-19 recovered cases and vaccinees of BBV152
Pragya D. Yadav, Gajanan N. Sapkal, Raches Ella, Rima R. Sahay, Dimpal A Nyayanit, Deepak Y. Patil, Gururaj Deshpande, Anita M. Shete, Nivedita Gupta, V. Krishna Mohan, Priya Abraham, Samiran Panda, Balram Bhargava
bioRxiv 2021.06.05.447177; doi: https://doi.org/10.1101/2021.06.05.447177

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Microbiology
Subject Areas
All Articles
  • Animal Behavior and Cognition (4237)
  • Biochemistry (9147)
  • Bioengineering (6786)
  • Bioinformatics (24025)
  • Biophysics (12137)
  • Cancer Biology (9545)
  • Cell Biology (13795)
  • Clinical Trials (138)
  • Developmental Biology (7642)
  • Ecology (11716)
  • Epidemiology (2066)
  • Evolutionary Biology (15518)
  • Genetics (10650)
  • Genomics (14332)
  • Immunology (9493)
  • Microbiology (22858)
  • Molecular Biology (9103)
  • Neuroscience (49032)
  • Paleontology (355)
  • Pathology (1484)
  • Pharmacology and Toxicology (2572)
  • Physiology (3849)
  • Plant Biology (8338)
  • Scientific Communication and Education (1472)
  • Synthetic Biology (2296)
  • Systems Biology (6196)
  • Zoology (1302)